Harvey RD, Rubinstein WS, Ison G, et al. Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis. ASCO Annual Meeting 2019, abstract LBA108.
Icotinib versus chemotherapie als adjuvante behandeling stadium II-IIIA EGFR-gemuteerd NSCLC
jan 2022 | Longoncologie